NXTC
NASDAQ
$5.40
Nextcure Inc (NXTC)
NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $20 (+270.37%)
Market Cap
$24M
Profit Margin
43.5%
Beta (5Y)
0.65
Price Chart
Valuation
Market Cap$24M
P/S9.52
P/B1.00
Profitability
Gross Profit (TTM)-$54M
EBITDA-$54M
Profit Margin43.5%
Operating Margin36.7%
EPS-$20.10
Growth & Risk
EPS 5Y CAGR-6.00%
FCF 5Y CAGR-1.80%
Beta (5Y)0.65
Sharpe Ratio0.72